Qiagen NV (QIA)

37.81 -0.81 (-2.10%)
Closed EUR Disclaimer

Qiagen NV Company Profile

Equity Type
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a collaboration with the U.S. FBI. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
Contact Information
Venlo,5912 PL Netherlands
31 77 355 6600
Top Executives
Stephane Bancel 48 2013 Independent Supervisory Director
Lawrence A. Rosen 64 2013 Independent Chairman of Supervisory Board
Toralf A. Haag 58 2021 Independent Member of the Supervisory Board
Elaine R. Mardis 62 2014 Independent Member of the Supervisory Board
Elizabeth Edith Tallett 75 2011 Independent Member of the Supervisory Board
Rick A. Bright 58 0000 Member of Scientific Advisory Board
Patrice Nordmann 0 0000 Member of the Scientific Advisory Board
Ross L. Levine 52 2016 Independent Member of the Supervisory Board & Chair of the Scientific Advisory Board
Neville Sanjana 0 0000 Member of the Scientific Advisory Board
Sarah A. Polonius-Teichmann 0 0000 Member of the Scientific Advisory Board
Eva Pisa 70 2022 Independent Member of the Supervisory Board
Eva van Pelt 59 2024 Independent Member of the Supervisory Board
Peter Klaus Kaspar 0 0000 Member of the Scientific Advisory Board
Bert van Meurs 63 2024 Independent Member of the Supervisory Board
Stephen H. Rusckowski 67 2023 Independent Member of Supervisory Board
Clear All
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.